Table 2. Published Clinical studies of... | American Society of Hematology

Table 2.

Published Clinical studies of TKI discontinuation in patients with CP-CML

Study trials of imatinib discontinuation	N	Treatment before discontinuation	TFR	Median follow-up time, mo
STIM1^27,28	100	IFN then imatinib for ≥3 y	43% at 6 mo	77
STIM1^27,28	100	IFN then imatinib for ≥3 y	38% at 60 mo	77
KIDS³¹	156		59% at 24 mo	27
TWISTER²⁹	40	Imatinib for ≥3 y	47% at 24 mo	42
ASTIM³⁰	80	Imatinib for ≥3 y	64% at 24 mo	23
ISAV⁴⁵	112	IFN	48% at 36 mo	22
EURO-SKI^33,*	755	TKI ≥3 y		Preliminary results 61% at 6 mo
STOP 2G-TKI pilot³⁴	60	Nilotinib or dasatinib	63% at 12 mo	47
STOP 2G-TKI pilot³⁴	60	Nilotinib or dasatinib	54% at 48 mo	47
ENESTFreedom³⁶	175	Nilotinib front line	52% at 11 mo	11
ENESTop^37,*	117	Second-line nilotinib (≥3 y total; ≥2 y nilotinib)	58% at 11 mo	11
DADI³⁵	156	Dasatinib	49% at 6 mo	20
DADI³⁵	156	Dasatinib	48% at 12 mo	20

Study trials of imatinib discontinuation	N	Treatment before discontinuation	TFR	Median follow-up time, mo
STIM1^27,28	100	IFN then imatinib for ≥3 y	43% at 6 mo	77
STIM1^27,28	100	IFN then imatinib for ≥3 y	38% at 60 mo	77
KIDS³¹	156		59% at 24 mo	27
TWISTER²⁹	40	Imatinib for ≥3 y	47% at 24 mo	42
ASTIM³⁰	80	Imatinib for ≥3 y	64% at 24 mo	23
ISAV⁴⁵	112	IFN	48% at 36 mo	22
EURO-SKI^33,*	755	TKI ≥3 y		Preliminary results 61% at 6 mo
STOP 2G-TKI pilot³⁴	60	Nilotinib or dasatinib	63% at 12 mo	47
STOP 2G-TKI pilot³⁴	60	Nilotinib or dasatinib	54% at 48 mo	47
ENESTFreedom³⁶	175	Nilotinib front line	52% at 11 mo	11
ENESTop^37,*	117	Second-line nilotinib (≥3 y total; ≥2 y nilotinib)	58% at 11 mo	11
DADI³⁵	156	Dasatinib	49% at 6 mo	20
DADI³⁵	156	Dasatinib	48% at 12 mo	20

EURO-SKI and ENESTop are currently submitted.